NCT06246968 - A Study of Pembrolizumab and Cryoablation in People With Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 29, 2024

Primary Completion Date

January 29, 2027

Study Completion Date

January 29, 2027

Conditions

Metastatic Breast CancerBreast CancerBreast Cancer Stage IVTriple Negative Breast CancerTriple Negative Breast NeoplasmsMetastatic Triple-Negative Breast CarcinomaLocally Advanced Breast CancerLocally Advanced Triple-Negative Breast Carcinoma

Interventions

DRUG

Pembrolizumab

Participants will receive Pembrolizumab as part of standard of care treatment.

DEVICE

Cryoablation

Cryoablation is a type of thermal ablation that is a minimally invasive alternative technique to surgical resection.

Trial Locations (7)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center (All protocol activites), New York

10604

RECRUITING

Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison

11553

RECRUITING

Memorial Sloan Kettering Nassau (Limited Protocol Activites), Rockville Centre

11725

RECRUITING

Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities ), Commack

07920

RECRUITING

Memorial Sloan Kettering Cancer Center at Basking Ridge (Limited Protocol Activities), Basking Ridge

07748

RECRUITING

Memorial Sloan Kettering Monmouth (Limited protocol activities), Middletown

07645

RECRUITING

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale

All Listed Sponsors

lead

Memorial Sloan Kettering Cancer Center

OTHER